Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

lisocabtagene maraleucel (Breyanzi)

lisocabtagene maraleucel is an FDA-licensed reference biologic from Juno Therapeutics, Inc. a Bristol Myer-Squibb Company.

351(a) biologicBLA 125714 Juno Therapeutics, Inc. a Bristol Myer-Squibb Company
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2021

Reference product

Originator biologic
Ask AI
351(a)BLA 125714

Breyanzi lisocabtagene maraleucel

Juno Therapeutics, Inc. a Bristol Myer-Squibb Company

View full reference-product record
Approved
Marketing
Rx
Center
CBER
Patents
None listed

Exclusivity & patent cliffs

Protection horizon
Ask AI
  1. Reference approval

    Approval date of the reference lisocabtagene maraleucel product.

    5 yr 11 mo ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    in 4 yr 7 mo

lisocabtagene maraleucel: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for lisocabtagene maraleucel.

Related FDA reference tools

Assyro Intelligence

Ask anything about lisocabtagene maraleucel

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo